As Low As $0
Out of Pocket
co-pay-caret
XEOMIN® - Important Safety Information

Adults With Blepharospasm

Disease
Overview
Clinical
Trials
Efficacy Safety Dosing

Demonstrated Safety in Adults With Blepharospasm

Safety was demonstrated in a randomized, double-blind, placebo-controlled trial of XEOMIN1,2

Common Adverse Reactions vs Placebo
in Treatment-Naïve Patients

Adverse reactions demonstrated in a trial of XEOMIN®

Common Adverse Reactions vs Placebo
in Patients Pretreated With Botox®

Adverse reactions demonstrated in a trial of XEOMIN®

Noninferiority Study: Safety of XEOMIN vs active comparator (Botox)

Most adverse reactions were mild or moderate2

Common Adverse Reactions vs Botox

The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.

References

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.
  2. Jankovic J, Comella CL, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm–a randomized trial. Mov Disord. 2011;26(8):1521-1528.
  3. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303-312.